First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

Summary

This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.

Timeline

Start

2026-02-10

Primary completion

2028-03-24

Completion

2030-03-26

Drugs

Indications